TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

NCT ID: NCT05338762

Last Updated: 2022-08-11

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 218 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-06-02
• Study Completion Date: 2022-08-03

Brief Summary

The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test.

When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.

Detailed Description

Participants who have been previously diagnosed with COVID-19 within the past 3 months through any FDA emergency use approved (EUA) assay test will eligible for inclusion in the study. A blood and fingerstick sample will be obtained from the participant and for subjects with a positive test and symptom onset of less than 30 days a repeat RT-PCR nasal pharyngeal swab sample will be taken. The fingerstick sample will be used onsite by qualified site staff to test the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test. These results will be compared to the whole blood sample sent to the lab which will be analysed for SARS CoV-2 neutralizing antibodies using the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit and the comparator Plaque Reduction Neutralization Test (PRNT) test.

Conditions

SARS-CoV2 Infection

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Current COVID-19 symptoms or SARS-CoV-2 in the last 30 days with a positive RT-PCR test

75 subjects will be enrolled who were diagnosed as SARS-CoV-2 with a positive RT-PCR nasal pharangeal test or are suspected of having a COVID-19 infection with symptom onset in the last 30 days. (Symptom onset 0-30 days)

This group of subjects will receive:

1. a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test

2. a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)

3. a nasal-pharangeal RT-PCR test

No interventions assigned to this group

Diagnosed with SARS-CoV-2 (COVID-19) in the past 3 months with a positive RT-PCR test

30 subjects will be enrolled who have been diagnosed with COVID-19 in the past 3 months and had a prior positive RT-PCR nasal pharangeal test. (Symptom onsent 31-90 days)

This group of subjects will receive:

1. a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test

2. a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT)

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. ≥ 18 years of age

2. Able and willing to provide written informed consent

3. Previously diagnosed as SARS-CoV-2 positive by any FDA EUA approved assay with a symptom onset date within the previous 30 days and who are willing to provide a nasopharyngeal swab for RT-PCR testing

4. Suspected of previous SARS-CoV-2 infection and willing to provide a nasopharyngeal swab for RT-PCR testing

5. Previously diagnosed as SARS-CoV-2 positive by a FDA EUA approved RT-PCR assay with a symptom onset date greater than 30 days and a known date of PCR sample collection and symptom severity

Exclusion Criteria

1. Any significant medical, psychological, or social condition which in the opinion of the investigator may preclude the subject from participating in the trial

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Syntactx

NETWORK

Sponsor Role: collaborator

MiCo BioMed Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jay Hahn, PhD

Role: STUDY_DIRECTOR

MiCo BioMed

Locations

Mississippi State University

Starkville, Mississippi, United States

Joy Internal Medicine

Englewood Cliffs, New Jersey, United States

WellNow Urgent Care

Cincinnati, Ohio, United States

WellNow Urgent Care

Columbus, Ohio, United States

WellNow Urgent Care

Dayton, Ohio, United States

Countries

United States

Other Identifiers

MIC-US-2021-001

Identifier Type: -

Identifier Source: org_study_id